RegMed Investors (RMi) went exclusive on July 27th!

Your complimentary subscription to RegMed Investors’ (RMi) reporting on the stem, cell and gene therapy and RegMed sector has expired.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

It’s up to you to choose the level of content access to provide a premium experience and value - don’t wait to exhale!

I also bring fresh perspectives that yield a whole that is greater than the sum of the parts as I convey a spectrum of factors that explain outcomes, analytical principles and analysis without the encumbrance of trading, investment or I-Banking.

So, after these years of following our facts … first and fast; be part of our “inner circle” as a subscriber!

Stay with me and join our coalition and have a seat at the appreciation table!

content_top

34 companies, 1 interpreter! Insight, foresight
and recommendation

Model Portfolio

content_middle

RegMed Investors’ model portfolio is designed specifically to allow stem and cell therapy investors to leverage the strategic insights and qualitative and quantitative synthesis that are relied on by institutional, retail and individual investors.

We track daily and monthly performance and market commentary incorporating quarterly tactical updates with buying and selling insights, plus risk and bench-marking analytics!

As market conditions change, RegMed Investors tactically re-allocates “signals” of the portfolio and provides updates with trading rationale!

content_right

September 8, 2014 - 3:18pm | Model Portfolio
RMi Model Portfolio and Trading List

footer

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry MCusker . Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of RegMed Investors (RM-i); who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other RM-i media services or reposting please email hwm@regmedinvestors.com.

Search form

RegMed Investors (RMi) went exclusive on July 27th!

Top Sections:

Model Portfolio